Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine and Biotype Diagnostics GmbH announce the completion of a licence agreement granting Biotype access to OGT patents for the detection of DNA sequence variations. The licence, which will remain valid for the lifetime of the patents, provides Biotype with certain rights with respect to SNP genotyping.
Sue Sutton, VP Business Development at OGT, said: “OGT continues to develop its licensing programme and is pleased to license our sequence variation patents to Biotype. These patents are an important part of OGT’s broad patent portfolio and, together with Biotype’s micro-array platform, gives customers access to a new, comprehensive way of detecting commercially important wood-rotting fungi.”
Wilhelm Zorgiebel, Executive Director at Biotype, commented: “We are pleased to enter into this licensing arrangement with OGT, a company that is recognised as being at the forefront of molecular technology. This agreement helps us to develop our own micro-array technology platform for various applications in medicine and analytics. Our first product, which is completely unique in the market, is the Mycotype BasidioQS Micro-array Detection Kit, which allows the fast and sensitive, simultaneous analysis of the 27 most important wood-rotting basidiomycetes in Europe.”
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. Clinical & Genomic Solutions: OGT’s Genefficiency is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high quality genomic data to customers worldwide.
The OGT CytoSure cytogenetics array, labelling and interpretation software products and services provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.
Biomarker Discovery: OGT has a proven pedigree in genomic technology, which, together with the experience gained through the purchase of Sense Proteomic in 2009, enables OGT to develop highly specific customised genomic and proteomic biomarker panels for cancer and other diseases. OGT develops these for clinical screening and companion diagnostics requirements, both for direct sale and also for collaboration with partner companies.
This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of US patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.
Biotype Diagnostic GmbH was founded in 1999. It is situated in the GebäudeEnsemble Deutsche Werkstätten Hellerau in the north of Dresden, Germany. The company specialises in genotyping and in molecular biological analysis employed in forensics, human or veterinary medicine, as well as in construction surveys.